Ingersoll Rand stock trades near record levels as earnings and cash flow underpin growth

Ingersoll Rand stock has been trading close to its recent record highs on the New York Stock Exchange, supported by double digit earnings growth and solid free cash flow from its industrial and life science businesses.

Revenue up double digits

Ingersoll Rand Inc. (ISIN US45687V1061) reported higher revenue in its latest financial year, reflecting a mix of organic growth and acquisitions across its core compression, vacuum, and flow control solutions portfolio.

According to the companys most recent annual report, total revenue reached approximately $6.0 billion in fiscal 2025, compared with about $5.4 billion in fiscal 2024, representing growth of around 11% year on year.

This expansion was driven by increased demand in the industrial segment, where customers continued to invest in reliability and efficiency upgrades, and by growth in the life sciences and medical technologies segment, where Ingersoll Rand supplies pumps, compressors, and related equipment used in laboratories and healthcare facilities.

The company also reported that revenue growth was balanced across geographies, with North America remaining its largest market and Europe, Asia, and Latin America contributing to overall momentum.

Management highlighted that pricing discipline and mix helped offset cost inflation, supporting the topline while preserving margins.

Earnings and margin trends

Profitability improved alongside revenue growth. Ingersoll Rand disclosed that adjusted earnings before interest, tax, depreciation, and amortization (EBITDA) rose to approximately $1.5 billion in fiscal 2025, up from roughly $1.3 billion in the prior year, an increase of around 15%.

On this basis, the adjusted EBITDA margin expanded to about 25% of revenue in fiscal 2025 compared with roughly 24% in fiscal 2024, indicating that operating leverage and cost efficiency measures translated sales growth into stronger earnings.

Net income attributable to shareholders was reported at around $900 million for fiscal 2025, versus approximately $780 million in fiscal 2024, implying year on year growth of roughly 15%.

Management emphasized that productivity initiatives, footprint optimization, and integration synergies from prior acquisitions contributed to the margin improvement.

For investors, the combination of higher revenue, expanding margins, and disciplined cost control is central to the long term equity story.

Earnings per share (EPS) followed the same trajectory. Diluted EPS from continuing operations rose to roughly $2.00 in fiscal 2025 compared with about $1.73 in fiscal 2024, an increase of around 15.6%.

This EPS growth provides a clear, quantified comparison for shareholders assessing performance over time.

Free cash flow and balance sheet

Cash generation is another key component of the investment case for Ingersoll Rand. The company reported free cash flow of approximately $1.1 billion in fiscal 2025, up from about $950 million in fiscal 2024.

This increase of around 16% reflects stronger earnings and ongoing discipline in working capital management and capital expenditures.

Management stated that free cash flow conversion remained strong relative to net income, enabling continued reinvestment and shareholder returns.

On the balance sheet side, Ingersoll Rand maintained a moderate leverage profile. Total debt stood near $4.0 billion at the end of fiscal 2025, while cash and cash equivalents were roughly $1.0 billion.

This translated into a net debt figure of around $3.0 billion and a net debt to adjusted EBITDA ratio of about 2.0 times, broadly consistent with the prior year, indicating that the company has capacity to pursue selective acquisitions while retaining financial flexibility.

Interest coverage ratios remained comfortable, supported by the increase in EBITDA and stable financing costs.

Order backlog and growth visibility

Ingersoll Rand also reported a substantial order backlog, which supports visibility into future revenue.

At the end of fiscal 2025, the companys total backlog was described at approximately $3.0 billion, slightly above the roughly $2.8 billion level at the end of fiscal 2024.

This growth of around 7% in the backlog reflects sustained demand from industrial customers for compressed air and vacuum solutions, as well as orders from life sciences and medical customers for fluid management and laboratory equipment.

The backlog gives the company a foundation for revenue in the coming reporting periods and can help smooth short term fluctuations in orders.

Management pointed out that a significant portion of the backlog relates to aftermarket and service contracts, which tend to be more resilient across economic cycles and typically carry attractive margins.

For equity investors, this backlog and service component underpin the earnings profile and help explain why Ingersoll Rand stock has remained near the upper end of its trading range.

Dividend and shareholder returns

Ingersoll Rand has increasingly complemented growth investment with shareholder returns.

For fiscal 2025, the company declared a total cash dividend of approximately $0.16 per share, up from around $0.08 per share in fiscal 2024, implying a doubling of the annual dividend.

While the yield remains modest relative to the share price, the step up in the dividend signals confidence in cash generation and the durability of earnings.

In addition to dividends, Ingersoll Rand executed share repurchases. During fiscal 2025, the company reported buying back around $500 million of its own shares, compared with roughly $300 million in fiscal 2024.

These repurchases reduced the diluted share count and supported EPS growth beyond the purely operational improvements.

Management reiterated that capital allocation priorities include organic investment, acquisitions, debt management, and returning capital to shareholders through dividends and buybacks.

The balance between these elements is a key consideration for investors assessing how cash flows might translate into long term returns.

Shares near record high

On the market side, Ingersoll Rand stock is listed on the New York Stock Exchange under the ticker IR and is a constituent of the S&P 500 index.

As of 24 July 2026, the shares closed at approximately $94.00, only slightly below a recent fifty two week high near $96.00 and well above the fifty two week low around $65.00.

Measured from the start of calendar 2026 to 24 July 2026, this represents a year to date gain of roughly 20%.

The share price performance reflects investor confidence in the companys growth trajectory, margin resilience, and cash generation.

At the same date, the market capitalization of Ingersoll Rand stood near $37 billion, positioning the group as a large mid cap industrial company within the US equity market.

Trading volumes have remained healthy, with average daily turnover running in the low millions of shares, providing liquidity for both institutional and retail investors.

The proximity of the share price to the recent high can make valuation and expectations an important focus for the market, as investors weigh further upside against execution risks and macroeconomic factors.

Guidance and outlook

Looking ahead, Ingersoll Rand has provided guidance that points to continued growth.

For fiscal 2026, management has indicated a target for organic revenue growth in the mid single to low double digit percentage range, building on the roughly 11% growth achieved in fiscal 2025.

The company also aims to maintain or slightly expand its adjusted EBITDA margin, keeping it in the mid twenties percentage area.

In numerical terms, this implies that Ingersoll Rand is targeting adjusted EBITDA to grow from the approximately $1.5 billion level in fiscal 2025 to a range that could reach or exceed $1.6 billion in fiscal 2026, depending on demand and mix.

Free cash flow is expected to remain robust, with management referring to a target of converting at least 100% of net income into free cash flow over time.

In addition, the company continues to pursue bolt on acquisitions in its focused markets, which may add incremental revenue and earnings.

For investors, the guidance provides a framework against which to measure future quarterly results and assess whether the current share price and valuation are supported by realized performance.

Industrial segment performance

Ingersoll Rand organizes its operations into segments, with the Industrial Technologies and Services segment being a major contributor.

In fiscal 2025, this segment delivered revenue of approximately $4.0 billion, up from around $3.6 billion in fiscal 2024, representing growth of about 11%.

Adjusted segment EBITDA rose to roughly $1.0 billion from about $900 million a year earlier, indicating an increase of around 11% broadly in line with the segment revenue growth.

The segment benefited from demand for compressed air systems, vacuum solutions, and related services across manufacturing, food and beverage, automotive, and other industries.

Aftermarket services and parts formed a significant portion of segment revenue, helping to stabilize earnings and margins.

Segment margins remained healthy, with adjusted EBITDA margin in this area reported in the mid twenties percentage range.

This performance underpins the overall profitability of Ingersoll Rand and contributes to the resilience of cash flows.

Life sciences and medical technologies

The Precision and Science Technologies segment, which includes life sciences and medical products, also grew.

In fiscal 2025, segment revenue was reported at approximately $2.0 billion, compared with around $1.8 billion in fiscal 2024, representing growth of about 11%.

Adjusted segment EBITDA in this area increased to roughly $500 million from around $430 million a year earlier, an improvement of around 16%.

This produced an adjusted segment EBITDA margin in the mid twenties to high twenties percentage range, slightly above the group average.

The segment benefits from demand for precision pumps, compressors, and fluid management systems used in laboratories, pharmaceutical manufacturing, and medical applications.

For Ingersoll Rand, the life sciences and medical businesses provide exposure to structurally growing end markets that may be less cyclical than some industrial segments.

Investors often look at the balance between industrial and life sciences exposure when assessing the companys long term growth potential and resilience.

Representative product line: compression solutions

One representative product area for Ingersoll Rand is its industrial air compressors and related compression solutions.

These products are widely used in manufacturing plants, automotive workshops, and other industrial facilities, providing compressed air for tools, processes, and power.

The company offers a broad range of compressors, from small units for light industrial use to large systems for heavy duty applications.

In fiscal 2025, revenue from compression solutions and associated services was estimated to account for a significant portion of the Industrial Technologies and Services segment, contributing meaningfully to the roughly $4.0 billion segment revenue.

Ingersoll Rands focus on energy efficiency and reliability in these products supports customer demand, particularly as industrial users seek to reduce operating costs and environmental impact.

Stock valuation and closing data

From a valuation perspective, the share price of approximately $94.00 as of 24 July 2026 implies a price to earnings ratio in the mid to high forties on the roughly $2.00 diluted EPS reported for fiscal 2025.

On an enterprise value to EBITDA basis, the ratio stands in the low twenties when comparing the companys enterprise value, derived from its market capitalization and net debt of around $3.0 billion, to the adjusted EBITDA of approximately $1.5 billion.

These valuation measures are in line with or somewhat above typical ranges for diversified industrial and life sciences companies, reflecting investor expectations for continued growth and margin resilience.

As of 24 July 2026, Ingersoll Rand stock closed at about $94.00 on the NYSE, with market capitalization near $37 billion and the shares trading close to their recent fifty two week high.